Luminex Corporation (LMNX), a developer of biological testing technologies, has commenced the commercial launch of its first pharmacogenetic test following its recent approval by the U.S. Food and Drug Administration (FDA). Pharmacogenetics is the study of genetic factors that influence an individual’s response to drugs. The test, dubbed the xTAG CYP2D6 Kit, has been designed to [...] (LMNX) Luminex Earns FDA Approval for New Diagnostic Test